Comparative evaluation of lesion enhancement using 1 M Gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T

Investigative Radiology

Volumn 44, Issue 5, 2009, Pages 251-256

  Attenberger, Ulrikel ^a,b   Runge, Val M ^a   Jackson, Carney B ^c   Baumann, Shannon ^a   Birkemeier, Krista ^a   Michaely, Henrik J ^d   Schoenberg, Stefan O ^d   Reiser, Maximilian F ^b   Wintersperger, Bernd J ^b  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

3 T; Brain; Contrast enhancement; Gadobutrol; Gadopentetate dimeglumine; Gadoterate meglumine; Magnetic resonance imaging; Neoplastic disease

Indexed keywords

GADOBUTROL; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTRAST ENHANCEMENT; CONTRAST TO NOISE RATIO; CONTROLLED STUDY; GLIOMA; IMAGE PROCESSING; MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SIGNAL NOISE RATIO;

EID: 67651047054     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31819ba711     Document Type: Article

References (42)

1. Wintersperger BJ, Runge VM, Biswas J, et al. Brain tumor enhancement in MR imaging at 3 Tesla: comparison of SNR and CNR gain using TSE and GRE techniques. Invest Radiol. 2007;42:558-563.
2. Runge VM, Biswas J, Wintersperger BJ, et al. The efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging: comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model. Invest Radiol. 2006;41:244-248.
3. Noebauer-Huhmann iM, Pinker K, Barth M, et al. Contrast-enhanced, highresolution, susceptibility-weighted magnetic resonance imaging of the brain: dose-dependent optimization at 3 Tesla and 1.5 Tesla in healthy volunteers. Invest Radiol. 2006;41:249 -255.
4. Biswas J, Nelson CB, Runge VM, et al. Brain tumor enhancement in magnetic resonance imaging: comparison of signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) at 1.5 versus 3 Tesla. Invest Radiol. 2005;40: 792-797.
5. Knopp MV, Runge VM, Essig M, et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison ofgadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2004;230:55-64.
6. Noebauer-Huhmann IM, Ba-Ssalamah A, Mlynarik V, et al. Magnetic resonance imaging contrast enhancement of brain tumors at 3 Tesla versus 1.5 Tesla. Invest Radiol. 2002;37:114-119.
7. Ba-Ssalamah A, Nobauer-Huhmann IM, Pinker K, et al. Effect of contrast dose and field strength in the magnetic resonance detection of brain metastases. Invest Radiol. 2003;38:415-422.
8. Runge VM, Clanton JA, Price AC, et al. The use of Gd DTPA as a perfusion agent and marker of blood-brain barrier disruption. Magn Reson Imaging. 1985;3:43-55.
9. Le Duc G, Corde S, Charvet AM, et al. In vivo measurement of gadolinium concentration in a rat glioma model by monochromatic quantitative computed tomography: comparison between gadopentetate dimeglumine and gadobutrol. Invest Radiol. 2004;39:385-393.
10. Runge VM, Muroff LR, Jinkins JR. Central nervous system: review of clinical use of contrast media. Top Magn Reson Imaging. 2001;12:231-263.
11. Lin SP, BrownJJ. MR contrastagents: physical and pharmacologic basics. JMagn Reson Imaging. 2007;25:884-899.
12. Bellin MF, Van Der Molen AJ. Extracellular gadolinium-based contrast media: an overview. Eur JRadiol. 2008;66:160-167.
13. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison ofmagnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724.
14. Kramer H, Michaely HJ, Requardt M, et al. Effects ofinjection rate and dose on image quality in time-resolved magnetic resonance angiography (MRA) by using 1.0M contrast agents. Eur Radiol. 2007;17:1394-1402.
15. Fenchel M, Franow A, Martirosian P, et al. 1 M Gd-chelate (gadobutrol) for multislice first-pass magnetic resonance myocardial perfusion imaging. Br J Radiol. 2007;80:884-892.
16. Boss A, Martirosian P, Gehrmann M, et al. Quantitative assessment of glomerular filtration rate with MR gadolinium slope clearance measurements: a phase I trial. Radiology. 2007;242:783-790.
17. Attenberger UI, Michaely HJ, Wintersperger BJ, et al. Three-dimensional contrast-enhanced magnetic-resonance angiography of the renal arteries: interindividual comparison of 0.2 mmol/kg gadobutrol at 1.5 T and 0.1 mmol/kg gadobenate dimeglumine at3.0 T. Eur Radiol. 2008;18:1260-1268.
18. Stalder AF, Elverfeldt DV, Paul D, et al. Variable echo time imaging: signal characteristics of 1-M gadobutrol contrast agent at 1.5 and 3T. Magn Reson Med. 2008;59:113-123.
19. Theisen D, Wintersperger BJ, Huber A, et al. Myocardial first pass perfusion imaging with gadobutrol: impact of parallel imaging algorithms on image quality and signal behavior. Invest Radiol. 2007;42:522-528.
20. Trattnig S, Ba-Ssalamah A, Noebauer-Huhmann IM, et al. MR contrast agent at high-field MRI (3 Tesla). Top Magn Reson Imaging. 2003;14:365-375.
21. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol. 2008;43:141-144.
22. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadoliniumbased contrast media. Invest Radiol. 2008;43:65-75.
23. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol. 2008;66:230-234.
24. Idee JM, Port M, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol. 2006;20:563-576.
25. Schmitt-Willich H. Stability of linear and macrocyclic gadolinium based contrast agents. Br J Radiol. 2007;80:581-582; author reply 584-585.
26. Tweedle MF. The ProHance story: the making ofa novel MRI contrastagent. Eur Radiol. 1997;7(suppl 5):225-230.
27. Idee JM, Port M, Medina C, et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology. 2008;248:77-88.
28. Morcos SK. Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol. 2008;66:175-179.
29. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium based MRI contrast agents in human serum at 37°C. Invest Radiol. 2008;43:817-828.
30. Olukotun AY, Parker JR, Meeks MJ, et al. Safety of gadoteridol injection: US clinical trial experience. J Magn Reson Imaging. 1995;5:17-25.
31. Herborn CU, Lauenstein TC, Ruehm SG, et al. Intraindividual comparison of gadopentetate dimeglumine, gadobenate dimeglumine, and gadobutrol for pelvic 3D magnetic resonance angiography. Invest Radiol. 2003;38:27-33.
32. Akeson P, Vikhoff B, Stahlberg F, et al. Brain lesion contrast in MR imaging. Dependence on field strength and concentration of gadodiamide injection in patients and phantoms. Acta Radiol. 1997;38:14-18.
33. Chang KH, Ra DG, Han MH, et al. Contrast enhancement of brain tumors at different MR field strengths: comparison of 0.5 T and 2.0 T. Am J Neuroradiol. 1994;15:1413-1419; discussion 1420-1413.
34. Haustein J, Laniado M, Niendorf HP, et al. Administration of gadopentetate dimeglumine in MR imaging of intracranial tumors: dosage and field strength. Am JNeuroradiol. 1992;13:1199-1206.
35. Wintersperger BJ, Runge VM, Biswas J, et al. Brain magnetic resonance imaging at 3 Tesla using BLADE compared with standard rectilinear data sampling. Invest Radiol. 2006;41:586-592.
36. Bottomley PA, Foster TH, Argersinger RE, et al. A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1-100 MHz: dependence on tissue type, NMR frequency, temperature, species, excision, and age. MedPhys. 1984;11:425-448.
37. Fischer HW, Rinck PA, Van Haverbeke Y, et al. Nuclear relaxation ofhuman brain gray and white matter: analysis of field dependence and implications for MRI. Magn Reson Med. 1990;16:317-334.
38. Frayne R, Goodyear BG, DickhoffP, et al. Magnetic resonance imaging at 3.0 Tesla: challenges and advantages in clinical neurological imaging. Invest Radiol. 2003;38:385-402.
39. Lu H, Nagae-Poetscher LM, Golay X, et al. Routine clinical brain MRI sequences for use at 3.0 Tesla. JMagn Reson Imaging. 2005;22:13-22.
40. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dime-glumine (magnevist), gadobutrol (gadovist), and gadobenate dimeglumine (multihance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol. 2006;41:213-221.
41. Runge VM, Patel MC, Baumann SS, et al. T1-weighted imaging ofthe brain at 3 Tesla using a 2-dimensional spoiled gradient echo technique. Invest Radiol. 2006;41:68-75.
42. Runge VM, Case RS, Sonnier HL. Advances in clinical 3-Tesla neuroimaging. Invest Radiol. 2006;41:63-67.